Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (ATAC-Seq)

ABSTRACT: SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (ATAC-Seq)

PROVIDER: PRJNA967355 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24441004_1.fastq.gz	Fastqsanger.gz
	SRR24441004_2.fastq.gz	Fastqsanger.gz
	SRR24441005_1.fastq.gz	Fastqsanger.gz
	SRR24441005_2.fastq.gz	Fastqsanger.gz
	SRR24441006_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (WES)

Project description:To investigate the impact of SETD2 mutations on clonal fitness in B actue lymphoblastic leukemia we generated cells lines with SETD KO using CRISPR/Cas9 system. We then performed phenotypic based assays as well as gene expression profiling, mutation burden, and chromtain accessibilty analysis using data obtained from RNA-seq, Whole exom sequencing following drug traetment, and ATAC-seq.

2024-05-01 | GSE231723 | GEO

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (ATAC-Seq)

2024-05-01 | GSE231721 | GEO

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (RNA-Seq)

2024-05-01 | GSE231720 | GEO

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia

Project description:SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia

| PRJNA967350 | ENA

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (WES)

Project description:SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (WES)

| PRJNA967354 | ENA

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (RNA-Seq)

Project description:SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia (RNA-Seq)

| PRJNA967353 | ENA

SETD2 Mutations Do Not Contribute to Clonal Fitness in Response to Chemotherapy in Childhood B Acute Lymphoblastic Leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-05-01 | GSE231724 | GEO

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2019-02-25 | PXD010175 | Pride

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2020-01-29 | MSV000084862 | MassIVE

Proteomics analysis on SETD2 loss induced ccRCC formation

Project description:Patients with polycystic kidney disease (PKD) encounter a high risk of clear cell renal cell carcinoma (ccRCC), a malignant tumor with dysregulated lipid metabolism. SET domain–containing 2 (SETD2) has been identified as an important tumor suppressor gene in ccRCC. However, the role of SETD2 in tumorigenesis during the transition from PKD to ccRCC remains largely unexplored. Herein, we performed metabolomics, lipidomics, transcriptomics and proteomics with SETD2 loss induced PKD-ccRCC transition mouse model. To characterize biological responses triggered by SETD2 deletion during PKD-ccRCC transition at the protein level, we conducted global proteomics studies.

2023-10-31 | PXD038966 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data